CAS: 313-67-7; 8-Methoxy-6-Nitrophenanthro[3,4-D][1,3]Dioxole-5-Carboxylic Acid

该化合物是一种自然产生的化合物,产自亚里士多洛契亚契亚氏家族的植物,主要以其存在于各种传统草药疗法中而闻名.该化合物的特点是独特的化学结构,包括一种含有氮原子的双环系统,有助于其生物活动.亚里士多洛基亚酸表现出肾中毒和致癌特性,引起严重的健康问题,特别是它与肾损伤和子宫癌的关系.其行动机制涉及DNA吸附的形成,导致诱变效应.由于这些不利影响,许多国家限制或禁止使用含有亚里士多洛奇酸的草药.该化合物通常以白色为白色,黄色结晶粉的形式出现,在有机溶剂中溶解,但在水中溶解性很差.鉴于其毒理学特征,研究继续探索其影响和对人类健康的影响,强调使用含有该物质的草药需要谨慎.

结构式图片

欧盟法规

ECHA物质ECHA物质化妆品禁用物质清单C&L通报REACH预注册

上下游产品

CAS号13395-02-3 马兜铃内酰胺I | CAS号35142-05-3 aristolic acid | CAS号3580-56-1 Phenanthro(3,4-... | CAS号1169-60-4 Phenanthro[4,3-... | CAS号85814-30-8 Benzo(f)-1,3-be... | CAS号38965-71-8 马兜铃酸A去甲基代谢产物

合成工艺路线路线简述

    📜8-Methoxy-6-Nitronaphtho[2,1-G][1,3]Benzodioxole-5-Carbaldehyde置于sodium Chlorite体系中,用 Aq. Phosphate Buffer,二甲基亚砜 作为反应溶剂,化学反应生成 马兜铃酸
    参考文献:马兜铃酸,其主要代谢物和相关化合物的全合成
    标题:马兜铃酸,其主要代谢物和相关化合物的全合成
    摘要:自希波克拉底时代以来,马兜铃属植物已被推荐用于治疗各种人类疾病.然而,许多物种会产生剧毒的马兜铃酸 (Aas),这些物质既具有肾毒性又具有致癌性.为了进行广泛的生物学研究,主要基于 Suzuki-Miyaura 偶联反应设计了一种合成 Aa 及其主要代谢物的通用方法.成功的关键在于制备一种常见的环-A 前体,即 2-硝基甲基-3-碘-4,5-亚甲基二氧基苯甲醇 (27)的四氢吡喃醚,它是通过氧化醛肟前体26.铃木-宫浦联轴器27与各种苯甲醛 2-硼酸酯的反应伴随着羟醛缩合/消除反应,直接得到所需的菲中间体.苯甲醇的脱保护,然后是两个连续的氧化步骤,得到所需的菲硝基羧酸.该方法用于合成 Aa I-Iv 和其他几种相关化合物,包括在 6 位带有氨基丙氧基的 A I 和 Aa Ii,它们是进一步转化为荧光生物探针所必需的.suzuki-Miyaura 偶联反应进一步成功应用于合成aa I 和
    DOI:10.1021/tx500122X

    海关参考信息

    专利信息


    专利号:US-10111441-B1
    优先权日:2018-04-18
    标 题:Synthesis of silver-PMMA nanocomposite film using herbal extract
    发明人:AWAD MANAL AHMED GASMELSEED; HENDI AWATIF AHMED; ORTASHI KHALID MUSTAFA OSMAN; SOLIMAN DINA WAFIQ AWAD
    权利人:UNIV KING SAUD
    摘要:The synthesis of a silver-PMMA nanocomposite film using herbal extract includes mixing an aqueous extract of Aristolochia bracteolate buds with an aqueous solution of silver nitrate, thereby reducing the silver ions to silver metal nanoparticles. A solution of the silver nanoparticles is added to a solution of PMMA [poly (methyl methacrylate)] in N′N-dimethylformamide (DMF) with stirring at 80° C. A brown solution of silver colloids develops, which is cast in a glass plate and the DMF is evaporated at room temperature, leaving a silver-PMMA nanocomposite film. Testing on water shows the silver-PMMA nanocomposite film prevents or inhibits growth of microbes, suggesting use as an antimicrobial or antibacterial agent, e.g., in water purification. In addition, testing by disc diffusion against E. coli and Bacillus cereus showed zones of inhibition, also suggesting use as an antimicrobial or antibacterial agent.

    专利号:WO-2024109736-A1
    优先权日:2022-11-21
    标题:Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
    发明人:CAO BIN; ZHAO LIYU; TIAN YE; DOU GUOSHENG; LU SIZHU; YANG JUN; XIE DEWEI; CHEN ZHAOQIANG; ZHANG QIHUA; WANG SHAOHUI; CHEN BIN; ZHANG PEIYU
    权利人:SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD
    摘要:The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefor and a use thereof. The compound of the present application can significantly reduce the integrated stress response (ISR) of cells and activate the activity of eIF2B, so that the protein in the cells tends to be synthesized normally, providing more possible drugs for ISR pathway-mediated diseases or condition eIF2B-related diseases, and/or diseases related to regulation of the activity or level of eIF2B activity or level, and regulation of the activity or level of the eIF2 pathway or ISR pathway.

    专利号:CN-113684221-B
    优先权日:2021-09-10
    标 题:Application of benzyl isoquinoline alkaloid and derivative thereof in synthesis of gene Ac6OMT

    专利号:SA-119400637-B1
    优先权日:2018-04-18
    标题 :synthesis of a thin layer of polymethyl methacrylate-silver nanocomposite using herbal extract

    专利号:SU-1731053-A3
    优先权日:1985-08-28
    标题 :Method for synthesis of methylenedihydroxyphenanthrene or theirs pharmaceutically compatible salts

    专利号:WO-2019076178-A1
    优先权日:2017-10-18
    标 题:Medical degradable polyurethane with adjustable degradation time and adjustable elongation at break
    发明人:ZHANG WENFANG
    权利人:COMSCAFFOLDS NANJING MEDICAL DEVICE CO LTD
    摘要:The invention provides a medical degradable polyurethane with adjustable degradation time and adjustable elongation at break, a preparation method and application thereof, and can adjust the proportion of each component in the polyurethane synthesis process and select different chain extenders. Control the performance of PU in a wide range, such as PU degradation time, elongation at break, strength, lubricity and hydrophilicity, etc., can choose different properties of medical degradable polyurethane according to the needs of regenerative medicine and medical devices implanted in the body. .

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Guan T, Huang K, Liu Y, Hou S, Hu C, Li Y, Zhang J, Zhao J, Zhang J, Wang R, Huang Y. Aristolochic acid inhibits Slit2-induced migration and tube formation via inactivation of Robo1/Robo2-NCK1/NCK2 signaling pathway in human umbilical vein endothelial cells. Toxicol Lett. 2019 Jan;300:51-58. doi: 10.1016/j.toxlet.2018.10.022. Epub 2018 Oct 28. doi: 10.1038/s41598-018-30628-x.
    3: Kholia S, Herrera Sanchez MB, Cedrino M, Papadimitriou E, Tapparo M, Deregibus MC, Brizzi MF, Tetta C, Camussi G. Human Liver Stem Cell-Derived Extracellular Vesicles Prevent Aristolochic Acid-Induced Kidney Fibrosis. Front Immunol. 2018 Jul 19;9:1639. doi: 10.3389/fimmu.2018.01639. eCollection 2018.
    4: Marin DE, Pistol GC, Gras M, Palade M, Taranu I. A comparison between the effects of ochratoxin A and aristolochic acid on the inflammation and oxidative stress in the liver and kidney of weanling piglets. Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1147-1156. doi: 10.1007/s00210-018-1538-9. Epub 2018 Jul 22. doi: 10.1016/j.chroma.2018.05.037. Epub 2018 May 18. doi: 10.1038/s41598-018-22298-6.

    合成参考文献


    参考文献:10.1007/s12245-009-0105-z
    摘要:Phua DH, Zosel A, Heard K. Dietary supplements and herbal medicine toxicities—when to anticipate them and how to manage them. International Journal of Emergency Medicine. 2009 Jun 10;2(2):69–76. doi: 10.1007/s12245-009-0105-z.
    摘要:Zhang C, Chen YP, Dong HR, Qiu CB. [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. Zhonghua Yi Xue Za Zhi. 2005 Sep 28;85(37):2601–6.
    参考文献:10.1038/aps.2011.74
    摘要:Shi H, Feng J. Aristolochic acid induces apoptosis of human umbilical vein endothelial cells in vitro by suppressing PI3K/Akt signaling pathway. Acta Pharmacologica Sinica. 2011 Jul 18;32(8):1025–30. doi: 10.1038/aps.2011.74.
    参考文献:10.3109/01480545.2011.556645
    摘要:Kuo CC, Huang JK, Chou CT, Cheng JS, Tsai JY, Fang YC, Hsu SS, Liao WC, Chang HT, Ho CM, Jan CR. Effect of bisphenol A on Ca(2+) fluxes and viability in Madin-Darby canine renal tubular cells. Drug Chem Toxicol. 2011 Oct;34(4):454–61. doi: 10.3109/01480545.2011.556645.
    参考文献:10.1155/2011/645361
    摘要:Marin-Kuan M, Ehrlich V, Delatour T, Cavin C, Schilter B. Evidence for a Role of Oxidative Stress in the Carcinogenicity of Ochratoxin A. Journal of Toxicology. 2011;2011():1–15. doi: 10.1155/2011/645361.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知